Key result
Tenecteplase significantly reduced the 7-day composite of death or hemodynamic decompensation compared to placebo (4.5% vs. 20%, p=0.04) in patients with acute submassive pulmonary embolism.
Why the study?
Does tenecteplase plus unfractionated heparin improve clinical and hemodynamic outcomes compared to placebo plus unfractionated heparin in patients with acute submassive pulmonary embolism?
Population
86 patients with acute submassive pulmonary embolism, mean age 54.35 ± 12.8 years, 70% male, single-center…
Comparison
Tenecteplase plus unfractionated heparin vs Placebo plus unfractionated heparin (UFH)
Design
RCT, randomized
Authors
Loading...
May support tenecteplase in select submassive PE; leaves open confirmation and safety in larger trials.
RCT (n=86)
Randomized
No
Does tenecteplase plus unfractionated heparin improve clinical and hemodynamic outcomes compared to placebo plus unfractionated heparin in patients with acute submassive pulmonary embolism?
Absolute Event Rate: 4.5% vs 20%
p-value: p=0.04
In patients with acute submassive pulmonary embolism, tenecteplase improves hemodynamic stability and right ventricular function and reduces hospital stay, but does not reduce mortality and increases the risk of minor bleeding.
Sinha et al. (2016) conducted an RCT in Acute submassive pulmonary embolism (n=86). Tenecteplase vs. Placebo was evaluated on Composite of death from any cause, hemodynamic decompensation or collapse within 7 days (p=0.04). Tenecteplase significantly reduced the 7-day composite of death or hemodynamic decompensation compared to placebo (4.5% vs. 20%, p=0.04) in patients with acute submassive pulmonary embolism.
Synapse has enriched one closely related paper. Consider it for comparative context: